BRPI0512180A - plasmìdio de dna; composição imunogênica para induzir uma resposta imune a antìgenos selecionados em um hospedeiro vertebrado; método de imunização de um hospedeiro invertebrado contra antìgenos selecionado; composição imunogênica para induzir uma resposta imune ao vìrus da imunodeficiência humana (hiv) em um hospedeiro vertebrado; método para imunizar um hospedeiro vertebrado contra antìgenos selecionados; composição imunogênica; e uso de uma composição imunogênica - Google Patents

plasmìdio de dna; composição imunogênica para induzir uma resposta imune a antìgenos selecionados em um hospedeiro vertebrado; método de imunização de um hospedeiro invertebrado contra antìgenos selecionado; composição imunogênica para induzir uma resposta imune ao vìrus da imunodeficiência humana (hiv) em um hospedeiro vertebrado; método para imunizar um hospedeiro vertebrado contra antìgenos selecionados; composição imunogênica; e uso de uma composição imunogênica

Info

Publication number
BRPI0512180A
BRPI0512180A BRPI0512180-9A BRPI0512180A BRPI0512180A BR PI0512180 A BRPI0512180 A BR PI0512180A BR PI0512180 A BRPI0512180 A BR PI0512180A BR PI0512180 A BRPI0512180 A BR PI0512180A
Authority
BR
Brazil
Prior art keywords
immunogenic composition
induce
immune response
immunizing
host
Prior art date
Application number
BRPI0512180-9A
Other languages
English (en)
Inventor
Maninder K Sidhu
John H Eldridge
Michael Egan
Zimra Israel
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0512180A publication Critical patent/BRPI0512180A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PLASMìDIO DE DNA; COMPOSIçãO IMUNOGêNICA PARA INDUZIR UMA RESPOSTA IMUNE A ANTìGENOS SELECIONADOS EM UM HOSPEDEIRO VERTEBRADO; MéTODO DE IMUNIZAçãO DE UM HOSPEDEIRO INVERTEBRADO CONTRA ANTìGENOS SELECIONADO; COMPOSIçãO IMUNOGêNICA PARA INDUZIR UMA RESPOSTA IMUNE AO VìRUS DA IMUNODEFICIêNCIA HUMANA (HIV) EM UM HOSPEDEIRO VERTEBRADO; MéTODO PARA IMUNIZAR UM HOSPEDEIRO VERTEBRADO CONTRA ANTìGENOS SELECIONADOS; COMPOSIçãO IMUNOGêNICA; E USO DE UMA COMPOSIçãO IMUNOGêNICA A invenção fornece um plasmídio de DNA compreendendo:(a) uma primeira unidade transcricional compreendendo uma seqüência de nucleotídeo que codifica um primeiro polipeptídeo operavelmente ligado a elementos regulatórios incluindo um primeiro promotor e um primeiro sinal de poliadenilação; (b) uma segunda unidade transcricional compreendendo uma seqüência de nucleotídeo que codifica um segundo polipeptídeo operavelmente ligado a elementos regulatórios incluindo um segundo promotor e um segundo sinal de poliadenilação; (c) uma terceira unidade transcricional compreendendo uma seqüência de nucleotídeo que codifica um terceiro polipeptídeo operavelmente ligado a elementos regulatórios incluindo um terceiro promotor e um terceiro sinal de poliadenilação; e onde o citado primeiro, o citado segundo e o citado terceiro promotor são derivados de diferentes unidades transcricionais; e onde o citado primeiro, o citado segundo e o citado terceiro sinal de poliadenilação são derivados e diferentes unidades transcricionais; A invenção também está relacionada a composições imunogênicas para induzir uma resposta imune ao HIV compreendendo as combinações de dois, três ou quatro p1asmídios, onde cada plasmídio está expressando um antígeno definido, que pode ser um antíqeno único ou a fusão de dois ou três antígenos.
BRPI0512180-9A 2004-06-17 2005-06-15 plasmìdio de dna; composição imunogênica para induzir uma resposta imune a antìgenos selecionados em um hospedeiro vertebrado; método de imunização de um hospedeiro invertebrado contra antìgenos selecionado; composição imunogênica para induzir uma resposta imune ao vìrus da imunodeficiência humana (hiv) em um hospedeiro vertebrado; método para imunizar um hospedeiro vertebrado contra antìgenos selecionados; composição imunogênica; e uso de uma composição imunogênica BRPI0512180A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58043804P 2004-06-17 2004-06-17
US62498304P 2004-11-03 2004-11-03
US66227505P 2005-03-16 2005-03-16
PCT/US2005/021168 WO2006009746A2 (en) 2004-06-17 2005-06-15 Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv

Publications (1)

Publication Number Publication Date
BRPI0512180A true BRPI0512180A (pt) 2008-02-12

Family

ID=35266872

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512180-9A BRPI0512180A (pt) 2004-06-17 2005-06-15 plasmìdio de dna; composição imunogênica para induzir uma resposta imune a antìgenos selecionados em um hospedeiro vertebrado; método de imunização de um hospedeiro invertebrado contra antìgenos selecionado; composição imunogênica para induzir uma resposta imune ao vìrus da imunodeficiência humana (hiv) em um hospedeiro vertebrado; método para imunizar um hospedeiro vertebrado contra antìgenos selecionados; composição imunogênica; e uso de uma composição imunogênica

Country Status (16)

Country Link
US (2) US20070190031A1 (pt)
EP (2) EP2116605B1 (pt)
JP (3) JP2008503211A (pt)
KR (1) KR101216278B1 (pt)
AR (1) AR049309A1 (pt)
AU (2) AU2005265008A1 (pt)
BR (1) BRPI0512180A (pt)
CA (1) CA2570114C (pt)
DK (1) DK2116605T3 (pt)
ES (1) ES2386507T3 (pt)
IL (1) IL180109A0 (pt)
MX (1) MXPA06014794A (pt)
PL (1) PL2116605T3 (pt)
PT (1) PT2116605E (pt)
TW (1) TW200613554A (pt)
WO (1) WO2006009746A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
EP2203187B1 (en) * 2007-10-25 2012-08-29 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Constructs containing multiple expression cassettes for cancer therapy
KR20100100868A (ko) * 2007-11-14 2010-09-15 브이지엑스 파마수티컬즈, 엘엘씨 전기천공에 의해 전달되는 ｄｎａ 백신에 의해 유도되는 항체의 생산 방법
US9816086B2 (en) * 2010-07-06 2017-11-14 The Ohio State University Dose and location controlled drug/gene/particle delivery to individual cells by nanoelectroporation
ES2791758T3 (es) 2011-12-22 2020-11-05 Hoffmann La Roche Organización de vectores de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos
WO2014109519A1 (ko) * 2013-01-10 2014-07-17 강원대학교산학협력단 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물
FR3004463A1 (fr) * 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
US10344285B2 (en) 2014-04-09 2019-07-09 Dna2.0, Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
DK3129487T3 (da) * 2014-04-09 2020-11-30 Dna Twopointo Inc Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
CA3001312A1 (en) 2015-10-08 2017-04-13 Dna2.0, Inc. Dna vectors, transposons and transposases for eukaryotic genome modification
JP2018038333A (ja) * 2016-09-08 2018-03-15 ライフテクノロジーズジャパン株式会社 細胞の作製方法、発現用ベクター及び細胞
JP2024511591A (ja) * 2021-03-16 2024-03-14 アストラゼネカ・アクチエボラーグ 合成プロモーターを使用する多重遺伝子発現の制御

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428952B1 (en) * 1983-09-15 2002-08-06 Institut Pasteur Methods and kits employing LAV antigens for the detection of HIV-1-specific antibodies
US6600023B1 (en) * 1983-09-15 2003-07-29 Institut Pasteur Antibody directed against HIV-1 P25 antigen
US5843638A (en) * 1983-12-05 1998-12-01 Institut Pasteur And Centre National De La Recherche Scientifique Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1).
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5034511A (en) * 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE423856T1 (de) * 1989-06-02 2009-03-15 Pasteur Institut Nukleotid-sequenzen von hiv-1, hiv-2 und siv retrovirusgenomen, ihre verwendung zur amplifizierung von pol-sequenzen dieser retroviren und zur in vitro diagnostik von diesen viren verursachten infektionen
US5169784A (en) * 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5158062A (en) 1990-12-10 1992-10-27 Ford Motor Company Adaptive air/fuel ratio control method
US5118816A (en) 1990-12-26 1992-06-02 American Cyanamid Company 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07502646A (ja) 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
HU219767B (hu) 1993-01-26 2001-07-30 Leslie R. Coney Készítmények és eljárások genetikai anyag sejtbe történő beviteléhez
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5547862A (en) * 1993-07-29 1996-08-20 Ambion Inc. Vectors containing multiple promoters in the same orientation
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5585263A (en) 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
ATE374253T1 (de) * 1994-10-20 2007-10-15 Pasteur Institut Nukleotiden-sequenzen aus retroviren-antigenen hiv-i gruppe (oder untergruppe) o
GB9517263D0 (en) * 1995-08-23 1995-10-25 Cancer Res Campaign Tech Expression systems
AU7450496A (en) * 1995-10-20 1997-05-07 Collagen Corporation Production of recombinant procollagen in yeast
US5965440A (en) 1995-12-07 1999-10-12 The General Hospital Corporation Controlled gene product delivery from a regulatable retroviral vector
EP0880360B1 (en) 1996-02-12 2002-10-09 Cobra Therapeutics Limited Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6225045B1 (en) 1996-05-13 2001-05-01 Ribotargets, Ltd. Assays for screening for inhibitors of HIV
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
AU729579B2 (en) 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CA2223029A1 (en) 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1003894A2 (en) 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU745805B2 (en) 1997-10-28 2002-04-11 Wyeth Compositions and methods for delivery of genetic material
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
ATE512231T1 (de) 1998-02-27 2011-06-15 Univ Pennsylvania Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
PT1061955E (pt) 1998-03-13 2005-08-31 Wyeth Corp Composicao de polinucleotido, metodo de preparacao e sua utilizacao
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DE69938044T2 (de) 1998-05-22 2009-01-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neue post-transkriptionelle regulationselemente und deren verwendung
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
EP1168918A4 (en) 1999-03-03 2002-08-21 Univ Pennsylvania VACCINE AND GENE THERAPY COMPOSITIONS AND METHOD FOR THEIR PRODUCTION AND USE
WO2000055378A1 (en) 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Lentiviral vector system for high quantity screening
US7446189B1 (en) 1999-04-30 2008-11-04 Institut De Recherches Cliniques De Montreal Nucleic acids encoding mutant human CD80 and compositions comprising the same
CA2395269C (en) 1999-12-23 2015-12-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
AU784679B2 (en) * 1999-12-23 2006-05-25 International Aids Vaccine Initiative Improvements in or relating to immune responses to HIV
US6589783B2 (en) * 2000-04-13 2003-07-08 Novagen, Inc. Multiple host expression vector
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
KR100815888B1 (ko) * 2000-07-14 2008-03-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｈｉｖ 보조 단백질을 암호화하는 ｄｎａ 백신
JP5052732B2 (ja) * 2000-08-14 2012-10-17 アメリカ合衆国 遺伝的免疫化のための免疫原性を強化するＨＩＶＥｎｖ、Ｇａｇ、およびＰｏｌの改変
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
ATE340271T1 (de) * 2001-10-22 2006-10-15 Nucleonics Inc Transfektionskinetik und strukturelle promotoren
WO2003048366A1 (en) * 2001-12-07 2003-06-12 Postech Foundation Sivmac239 immunogenic plasmids and aids dna vaccine containing the same
CN1490056A (zh) * 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
CN1764474B (zh) * 2003-03-26 2011-02-02 惠氏公司 免疫原性组合物及方法
WO2005034992A2 (en) * 2003-09-15 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv vaccines based on env of multiple clades of hif
WO2005068634A1 (en) * 2004-01-16 2005-07-28 Pradeep Seth Hiv-1 indian subtype c vaccine constructs for use in humans

Also Published As

Publication number Publication date
US8623382B2 (en) 2014-01-07
WO2006009746A3 (en) 2006-05-11
JP5264840B2 (ja) 2013-08-14
WO2006009746A9 (en) 2006-03-02
EP2116605B1 (en) 2012-06-06
AU2010241303A1 (en) 2010-11-25
PL2116605T3 (pl) 2012-10-31
CA2570114A1 (en) 2006-01-26
US20070190031A1 (en) 2007-08-16
PT2116605E (pt) 2012-07-24
IL180109A0 (en) 2007-05-15
CA2570114C (en) 2013-10-08
KR20070029253A (ko) 2007-03-13
DK2116605T3 (da) 2012-07-09
ES2386507T3 (es) 2012-08-22
JP2010265313A (ja) 2010-11-25
MXPA06014794A (es) 2007-02-16
JP2011115178A (ja) 2011-06-16
EP2116605A2 (en) 2009-11-11
EP1763580A2 (en) 2007-03-21
US20120003265A1 (en) 2012-01-05
AU2005265008A1 (en) 2006-01-26
AU2010241303B2 (en) 2012-09-27
WO2006009746A2 (en) 2006-01-26
KR101216278B1 (ko) 2012-12-28
EP2116605A3 (en) 2010-01-06
TW200613554A (en) 2006-05-01
JP2008503211A (ja) 2008-02-07
AR049309A1 (es) 2006-07-12

Similar Documents

Publication Publication Date Title
Freyn et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice
Del Campo et al. OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes
King et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
Hashem et al. A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model
Heraud et al. Subunit recombinant vaccine protects against monkeypox
BRPI0512180A (pt) plasmìdio de dna; composição imunogênica para induzir uma resposta imune a antìgenos selecionados em um hospedeiro vertebrado; método de imunização de um hospedeiro invertebrado contra antìgenos selecionado; composição imunogênica para induzir uma resposta imune ao vìrus da imunodeficiência humana (hiv) em um hospedeiro vertebrado; método para imunizar um hospedeiro vertebrado contra antìgenos selecionados; composição imunogênica; e uso de uma composição imunogênica
Lambe et al. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1
JP7326157B2 (ja) Ｈｂｖワクチン
Warimwe et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice
Wang et al. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
CN107847575B (zh) 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物
Guirakhoo et al. A Novel SARS-CoV-2 multitope protein/peptide vaccine candidate is highly immunogenic and prevents lung infection in an AAV hACE2 mouse model and non-human primates
Magnusson et al. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice
Chiang et al. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement
WO2021178623A1 (en) Immunogenic compositions against severe acute respiratory syndrome coronavirus 2
Chiang et al. Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
Valdés et al. Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus?
WO2005046621A3 (en) Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
Feng et al. Immune strategies using single-component LipL32 and multi-component recombinant LipL32-41-OmpL1 vaccines against leptospira
Ying et al. A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ. 1.1 and XBB. 1.5 infection and disease in mice and hamsters
BRPI0904020B8 (pt) composição vacinal contra o vírus da dengue, e, kit
Galvez-Romero et al. Addition of C3d-P28 adjuvant to a rabies DNA vaccine encoding the G5 linear epitope enhances the humoral immune response and confers protection
ATE520708T1 (de) Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
AU2017315238A1 (en) Immunogenic composition

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/63

Ipc: C12N 15/63 (2006.01), A61K 39/21 (2006.01), A61P 3

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements